Information Provided By: 
Fly News Breaks for June 11, 2015
BIIB
Jun 11, 2015 | 08:04 EDT
Leeirnk lowered its price target for Biogen to $512 from $532 to reflect Tecfidera prescription trends in Q2. The firm points out, however, that shares are around the same levels that they were prior to BIIB037 generating "a lot of buzz." BIIB037 is being developed as a disease modification treatment for Alzheimer's disease. Leerink reiterates an Outperform rating on Biogen.
News For BIIB From the Last 2 Days
